“Glucose-responsive – so-called smart – insulins are regarded as the holy grail of insulin as they would come as close to a ...

New data from the QWINT clinical trial may get Eli Lilly closer to bringing a once-weekly insulin injection to the US, ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Key drivers include technological advancements and evolving healthcare policies. The global market for short-acting insulin ...

The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...

and it now consists of pramlintide 0.6 mg/mL buffered at pH 4.0. The basic pharmacokinetics and pharmacodynamics of a 60-µg dose of the new pramlintide formulation when mixed with insulin remain ...

It was recognized that rapid innovation in this field and the continuous introduction of new features dictate ... of their pumps with specific insulin formulations and infusion sets systematic ...

Technological Innovations: Development of novel insulin formulations and delivery systems, such as insulin pumps and smart pens, are expanding the market.

Diabetes affects over 37 million people in the U.S., with many of them living with type 2 diabetes. This form of diabetes ...

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...

Diabetes affects millions of Americans, with 1.4 million new cases diagnosed each year. This chronic condition is one of the ...